Advice
following an abbreviated submission:
budesonide suppository (Budenofalk®) is accepted for use within NHSScotland.
Indication under review: short-term treatment of mild to moderate acute ulcerative colitis limited to the rectum (ulcerative proctitis) in adult patients.
Budesonide offers an additional treatment choice in the therapeutic class of topical corticosteroids.
Download detailed advice336KB (PDF)
Medicine details
- Medicine name:
- budesonide suppository (Budenofalk)
- SMC ID:
- SMC2855
- Indication:
Short-term treatment of mild to moderate acute ulcerative colitis limited to the rectum (ulcerative proctitis) in adult patients.
- Pharmaceutical company
- Dr Falk Pharma UK
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 November 2025